Treating ischaemia‐reperfusion injury with prostaglandin E1 reduces the risk of early hepatocellular carcinoma recurrence following liver transplantation
Alimentary Pharmacology & Therapeutics2015Vol. 42(9), pp. 1101–1110
Citations Over TimeTop 14% of 2015 papers
Abstract
Treating hepatic ischaemia-reperfusion injury with alprostadil reduces the risk of early HCC recurrence following LT. In particular patients with HCC exceeding the Milan criteria seem to benefit from PGE1-treatment. The molecular mechanisms of the anti-tumour effects need to be further assessed.
Related Papers
- → Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma(2011)62 cited
- → Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation(2018)19 cited
- To Evaluate The Effectiveness Of Different Criteria For Slavage Liver Transplantation For Hepatocellular Carcinoma Recurrence After Liver Resection(2013)
- → Is liver transplantation superior to liver resection for hepatocellular carcinoma within Milan criteria?(2022)
- → P0046 : Response to loco-ablative treatment of HCC prior to liver transplantation is associated with low recurrence rates in patients exceeding the milan criteria(2015)